pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › AZN

AZN PDUFA Date: Ultomiris (ravulizumab)

FDA decision (PDUFA) target 2026-12-31 · AstraZeneca PLC · Immunoglobulin A nephropathy

AZN run-up into the PDUFA (last ~120 days)

$208.67$176.28
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-31
Drug / candidateUltomiris (ravulizumab)
IndicationImmunoglobulin A nephropathy
CompanyAstraZeneca PLC
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT06291376 · nan

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the AZN PDUFA date?
The FDA PDUFA target date for AZN (AstraZeneca PLC) is 2026-12-31 for Ultomiris (ravulizumab). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is AZN's drug Ultomiris (ravulizumab)?
Ultomiris (ravulizumab) is AstraZeneca PLC's candidate under FDA review for Immunoglobulin A nephropathy.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.